Immunogenicity and Efficacy of Monovalent and Bivalent Formulations of a Virus-Like Particle Vaccine against SARS-CoV-2

Virus-like particles (VLPs) offer great potential as a safe and effective vaccine platform against SARS-CoV-2, the causative agent of COVID-19. Here, we show that SARS-CoV-2 VLPs can be generated by expression of the four viral structural proteins in a mammalian expression system. Immunization of mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Resch, Matthew D., Wen, Ke, Mazboudi, Ryan, Mulhall Maasz, Hannah, Persaud, Mirjana, Garvey, Kaitlyn, Gallardo, Leslie, Gottlieb, Paul, Alimova, Aleksandra, Khayat, Reza, Morales, Jorge, Bielefeldt-Ohmann, Helle, Bowen, Richard A., Galarza, Jose M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782034/
https://www.ncbi.nlm.nih.gov/pubmed/36560407
http://dx.doi.org/10.3390/vaccines10121997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782034/
https://www.ncbi.nlm.nih.gov/pubmed/36560407
http://dx.doi.org/10.3390/vaccines10121997

Ejemplares similares